Allegiant Travel Company - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Allegiant Travel Company on September 4, 2020, reporting events occurring on September 1, 2020. The filing discloses the entry into material definitive employment agreements with two senior executives.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation terms.
Material Changes and Agreements
On September 1, 2020, the Company entered into three-year employment agreements with:
- Robert Wilson: Executive Vice President and Chief Information Officer.
- Scott DeAngelo: Executive Vice President and Chief Marketing Officer.
Key terms of the agreements include:
- Base Salary: $260,000 per year for each executive.
- Compensation Structure: Total annual compensation matches 2019 levels, with over 75% delivered via stock grants.
- Equity Grants (Mr. Wilson): 8,400 restricted shares initially, plus additional shares on the first and second anniversaries valued at $1,085,000 each.
- Equity Grants (Mr. DeAngelo): 7,450 restricted shares initially, plus additional shares on the first and second anniversaries valued at $960,000 each.
- Vesting: Three-year vesting schedule with acceleration provisions for death, disability, termination without cause, resignation with good reason, or change in control.
- Severance: In the event of termination without cause or resignation with good reason, executives receive base salary and benefits through the end of the three-year term (minimum six months).
- CARES Act Compliance: All compensation is subject to CARES Act executive compensation limits while applicable. Additional grants of 7,500 shares are contingent on the expiration of these limits.
- Restrictions: Noncompete and nonsolicitation clauses apply during the term and for one year thereafter.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of general business risks. The primary contingency noted is the applicability of CARES Act compensation limits, which affects the timing of additional equity grants.
Investor Verification Checklist
- Verify the current status of CARES Act executive compensation limits and their impact on the scheduled additional equity grants.
- Confirm the total number of shares outstanding and the dilution impact of the restricted stock grants described.
- Review the Company's most recent 10-Q or 10-K for actual 2019 compensation levels to validate the "total annual compensation" baseline.
- Monitor future filings for any changes in executive leadership or modifications to these agreements.